Jeffrey Tillinghast, MD
Allergy & Immunology · Saint Louis, MONPI 1447393301
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $258,795 of the $277,801 with a category attached, or 93.2%. Cipla USA Inc. accounts for 91.4% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2024 at $255,569 and has fallen 99.4% since, to $1,425 in 2025. Among allergy & immunology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 593 payments — averaging $468.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$254K
- AstraZeneca$5K
- Teva Pharmaceuticals USA, Inc.$3K
- Boehringer Ingelheim$3K
- Chiesi USA, Inc.$2K
- Genentech USA, Inc.$2K
- plus $10K from 36 others
Across 1,197 payments — averaging $8966.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4M
- Bavarian Nordic A/s$1.2M
- Romark Laboratories, LC$890K
- Teva Pharmaceuticals USA, Inc.$877K
- Amphastar Pharmaceuticals, Inc.$786K
- Novartis$732K
- plus $2.2M from 12 others
What the payments were for
- Consulting fees$1,6371%
- Speaking & faculty fees$258,79593%
- Travel & lodging$6,1602%
- Food & beverage$11,1374%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 7 | $253,995 |
| AstraZeneca | 94 | $4,932 |
| Teva Pharmaceuticals USA, Inc. | 5 | $2,672 |
| Boehringer Ingelheim | 18 | $2,671 |
| Chiesi USA, Inc. | 3 | $1,692 |
| Genentech USA, Inc. | 20 | $1,651 |
| Novartis | 26 | $1,593 |
| Astrazeneca UK Limited | 8 | $1,541 |
| GSK | 111 | $1,518 |
| Regeneron Healthcare Solutions, Inc. | 31 | $845 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $830 |
| Sanofi | 34 | $648 |
| CSL Behring | 23 | $634 |
| Pfizer | 36 | $467 |
| Grifols USA, LLC | 15 | $309 |
| Amgen | 12 | $246 |
| AbbVie | 9 | $209 |
| Pharming Healthcare, Inc. | 9 | $206 |
| Mylan Specialty L.p. | 12 | $188 |
| Optinose US, Inc. | 11 | $185 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $121 |
| Kaleo, Inc. | 7 | $100 |
| Lilly USA, LLC | 4 | $89 |
| Merck | 4 | $81 |
| Hospira, Inc. | 2 | $43 |
| Covis Pharma GmbH | 2 | $32 |
| Seqirus USA Inc | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Biocryst US Sales Co., LLC | 1 | $25 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| LEO Pharma Inc. | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| ADMA Biomanufacturing LLC | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Alk-abello, Inc | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Organon | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$277,801 in reported general payments places this provider in the 95th percentile of 61 allergy & immunology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 43 | $212,490 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $152,624 |
| Dupixent SyringeDupilumab | 24 | $87,610 |
| Breo ElliptaFluticasone/Vilanterol | 98 | $68,819 |
| EliquisApixaban | 60 | $45,696 |
| OzempicSemaglutide | 35 | $43,446 |
| Spiriva RespimatTiotropium Bromide | 45 | $31,371 |
| FarxigaDapagliflozin Propanediol | 25 | $28,019 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $18,626 |
| Arnuity ElliptaFluticasone Furoate | 29 | $13,129 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 40 | $9,911 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $9,223 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $8,267 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $3,742 |
| Epinephrine | 25 | $3,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Arexvy | $1,518 | $244,483284 claims |
| AstraZenecaFarxiga, Symbicort | $4,932 | $46,64565 claims |
| PfizerEliquis | $467 | $45,69660 claims |
| Novo NordiskOzempic | $20 | $43,44635 claims |
| Boehringer IngelheimSpiriva Respimat | $2,671 | $31,37145 claims |
| AbbVieSynthroid | $209 | $1,39624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 allergy & immunology providers in Missouri.
Other allergy & immunology in Saint Louis
- H James WednerSaint Louis$420K
- Manoj WarrierSaint Louis$316K
- Aaron Ver HeulSaint Louis$28K
- Peggy KendallSaint Louis$20K
- Michael BortsSaint Louis$17K
- Jeremy KatcherSaint Louis$16K
- Elyra FigueroaSaint Louis$11K
- Barbara JostSaint Louis$9K
- Maya JerathSaint Louis$9K
- Cheshil DixitSaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.